The purpose of this study is to compare any good and bad effects of receiving the drugs dabrafenib and trametinib continuously to receiving dabrafenib and trametinib with a break in treatment. Dabrafenib and trametinib are similar to vemurafenib and have been tested together and found to be safe and effective for patients with advanced melanoma. The combination has been approved by the FDA for the treatment of advanced melanoma. This study is testing whether receiving dabrafenib and trametinib with a break in treatment could extend the time before your cancer gets worse.

The purpose of this study is to find out more about the effects of AMG 228 in people that have advanced non-small cell lung cancer, head and neck cancer, melanoma, colon cancer, or bladder cancer. AMG 228 is an experimental drug that is being developed to stimulate the body’s immune system to kill cancer cells. This study is the first to test AMG 228 in people. This study will look at what doses of AMG 228 are safe for people to take and whether it causes any side effects.

The primary purpose of this research study is to assess how safe and well tolerated the study drugs, INCB024360 and nivolumab, are when given in combination in patients who have advanced or metastatic solid tumors. The study will also assess how well INCB024360 in combination with nivolumab works in preventing disease progression patients with melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, head and neck squamous cell carcinoma, ovarian cancer and diffuse large B cell lymphoma.

The primary purpose of this research study is to gather information on the safety and effect of TH-302 on your cancer. This study will also look at how the drug is processed in the body. In addition, this study will collect data from blood, tumor, and imaging studies about your specific cancer such as the level of oxygen that is present. These data may help to predict in the future which patients with advanced melanoma may be more likely to benefit from TH-302.

The primary purpose of this research study is to assess how safe and well tolerated the study drug, IDH305, is when given to patients who have advanced tumors that harbor IDH1R132 mutations. Pre-clinical data suggest the importance of these mutations in maintaining cancer. The hypothesis of this research study is inhibiting the mutant IDH1 mutation in these tumors will result in anti-tumor activity.